Anti-SARS-CoV-2 vaccination in people with multiple sclerosis: Lessons learnt a year in.

It has been over a year since people with multiple sclerosis (pwMS) have been receiving vaccines against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). With a negligible number of cases in which vaccination led to a relapse or new onset MS, experts around the world agree that the potential consequences of COVID-19 in pwMS by far outweigh the risks of vaccination. This article reviews the currently available types of anti-SARS-CoV-2 vaccines and the immune responses they elicit in pwMS treated with different DMTs. Findings to date highlight the importance of vaccine timing in relation to DMT dosing to maximize protection, and of encouraging pwMS to get booster doses when offered.

Informations de copyright

Copyright © 2022 Pugliatti, Hartung, Oreja-Guevara, Pozzilli, Airas, Alkhawajah, Grigoriadis, Magyari, Van Wijmeersch, Zakaria, Linker, Chan, Vermersch and Berger.

Déclaration de conflit d'intérêts

MP has received honoraria, consulting fees or travelling costs from Bayer, Biogen, Sanofi-Genzyme, Teva, Merck and Almirall. CO-G has received speaker and consultation fees from Biogen Idec, Celgene, Sanofi-Genzyme, Novartis, Roche, Merck and Teva. CP has served on scientific advisory boards for Novartis, Merck, Biogen, Bristol Myers Squibb, Roche, Janssen, Alexion, has received funding for travel and speaker honoraria from Merck, Biogen, Bristol Myers Squibb, Roche, Almirall, Janssen, Alexion and Novartis, and receives research support from Merck, Biogen, Novartis, Roche and Almirall. LA has received institutional research support from Novartis, Genzyme and Merck, and compensation for lectures and consulting fees from Novartis, Sanofi Genzyme, Merck, Biogen, Roche and Janssen. MA has received speaker honoraria, consulting fees, and/or educational travel support from Biogen, Merck, Sanofi-Genzyme, Roche, Novartis, Hikma and SAJA. NG has received honoraria and travel support, consultancy and lecture fees from Biogen Idec, Biologix, Novartis, Teva, Bayer, Merck Serono, Genesis Pharma, Sanofi – Genzyme, Roche, Elpen. He has also received research grants from Biogen Idec, Novartis, Teva, Merck Serono, Genesis Pharma, Sanofi – Genzyme and Roche. MM has served on scientific advisory boards for Sanofi, Novartis and Merck. She has received honoraria for lecturing from Biogen, Merck, Novartis, Roche, Genzyme and BMS. BW has received Research and Travel Grants, Honoraria for MS-Expert Advice and Speakers Fees from: Almirall, Actelion/Janssen, Bayer, Biogen, Celgene/BMS, Merck, Novartis, Roche, Sanofi-Genzyme and Teva. AC has received speakers’/board honoraria from Actelion (Janssen/J&J), Almirall, Bayer, Biogen, Celgene (BMS), Genzyme, Merck KGaA (Darmstadt, Germany), Novartis, Roche, and Teva, all for hospital research funds. He received research support from Biogen, Genzyme, and UCB, the European Union, and the Swiss National Foundation. PV has received honoraria and consulting fees from Biogen, Sanofi-Genzyme, Novartis, Teva, Merck, Roche, Imcyse, AB Science and BMS-Celgene. He also receives research support from Novartis, Sanofi-Genzyme and Roche. TB has received honoraria and consulting fees from Almirall, Bayer, Biogen, Biologix, Bionorica, Celgene/BMS, GSK, GW/Jazz Pharma, Horizon, MedDay, Merck, Novartis, Octapharma, Roche, Sandoz, Sanofi-Genzyme, TEVA, TG Therapeutics and UCB. He has received institutional research support from Almirall, Biogen, Bayer, Celgene/BMS, Merck, Novartis, Roche, Sanofi-Genzyme and Teva, and has participated in clinical trials sponsored by Alexion, Bayer, Biogen, Celgene/BMS, Merck, Novartis, Octapharma, Roche, Sanofi-Genzyme and Teva. The remaining authors declare that the research was conducted in the absence of any commercial or financial relationships that could be constructed as a potential conflict of interest.